Endometriosis Socioeconomic Impact: The Real Cost to Women's Lives, Work, and Wallets

How Common Is Endometriosis, and Why Does That Number Matter Economically?

Endometriosis affects an estimated 190 million women and girls globally, making it one of the most prevalent gynecological conditions on earth. That number is not a demographic footnote. It represents a workforce, a generation of caregivers, a population of women who are being asked to absorb a disease burden that the healthcare system has, for decades, consistently underpriced and under-researched.

In the United States alone, prevalence estimates range from 6 to 10 percent of women of reproductive age, with ACOG noting that approximately 1 in 10 women are affected. Because the disease can only be confirmed surgically, these figures almost certainly undercount true burden. Women with milder symptoms, women with limited healthcare access, and women whose pain has been normalized by clinicians all fall out of official counts.

Why Prevalence Drives Economics

The sheer number of women affected means the aggregate economic cost is enormous even if individual costs appear manageable in isolation. When a 2011 study published in Human Reproduction calculated total costs for women with endometriosis in the United States, the mean annual cost per patient reached approximately $10,321, split roughly equally between direct healthcare expenditure and indirect costs from lost productivity. That figure has only climbed with inflation.

The economic argument is also a health equity argument. Women who cannot afford diagnostic laparoscopy, who lack paid sick leave, or who live in states with limited specialist access face compounding disadvantage. A disease that already takes 7 to 10 years to diagnose becomes even harder to manage when financial barriers delay each step further.

The Diagnosis Delay: Years of Costs Before Treatment Even Begins

The single most economically damaging feature of endometriosis is not the disease itself. It is the gap between symptom onset and confirmed diagnosis, which research published in BJOG and reviewed by the World Endometriosis Research Foundation consistently places at 7 to 10 years.

During those years, women are not simply waiting. They are cycling through emergency department visits, primary care appointments, trial-and-error pain management, and specialist referrals that frequently miss the underlying diagnosis. Each encounter carries a cost. Each misdiagnosis, whether irritable bowel syndrome, anxiety, or "normal period pain," routes women through treatment pathways that do not address the source.

What Happens During the Delay

A woman who develops symptoms at 16 and receives a confirmed diagnosis at 26 has spent a decade accumulating costs without a clear treatment target. Those costs include:

• Over-the-counter analgesics used in quantities far beyond manufacturer recommendations
• Multiple rounds of hormonal contraceptives prescribed empirically, not diagnostically
• Gastrointestinal workups for bowel symptoms caused by rectovaginal disease
• Mental health treatment for anxiety and depression that may be driven, at least in part, by undertreated chronic pain
• Emergency visits during severe dysmenorrhea or rupture events

A 2017 analysis in the American Journal of Obstetrics and Gynecology found that women with endometriosis used significantly more healthcare resources across all categories compared with matched controls, and that this excess use began years before formal diagnosis.

The Diagnostic Odyssey by Life Stage

Adolescence and young adulthood. Teens with endometriosis are frequently told their pain is "just cramps." ACOG's Committee Opinion on Endometriosis in Adolescents acknowledges this dismissal pattern and calls for clinician education to reduce it. The result is that many women enter their twenties already behind, having lost years of potential diagnosis and early intervention.

Reproductive years. Women in their twenties and thirties who are actively building careers and, in many cases, attempting pregnancy face the dual burden of disease management and fertility concerns. This intersection, discussed further below, creates compounding economic pressure precisely when earning potential is rising.

Perimenopause. Endometriosis does not reliably resolve at menopause. Some women experience symptom persistence or recurrence, particularly those with deeply infiltrating disease or prior surgical management. Hormone therapy decisions in perimenopause become more complicated for women with endometriosis, adding specialist consultation costs that women without the condition do not face.

Direct Healthcare Costs: What Women Actually Pay

Direct costs are the line items on an EOB (explanation of benefits) or a medical bill. For women with endometriosis, these accumulate across several categories.

Surgical Costs

Laparoscopic surgery remains the gold standard for both diagnosis and treatment. ASRM's Practice Committee documents on endometriosis note that excision of lesions offers superior long-term outcomes compared to ablation, but excision requires surgeons with specialized training, and those surgeons are concentrated in academic centers and major cities. A woman in a rural area may need to travel, take additional time off work, and pay out-of-network rates.

Out-of-pocket surgical costs, even with insurance, commonly run $3,000 to $7,000 per procedure. Because lesion recurrence rates approach 50% within 5 years, many women face multiple surgeries across their lifetime.

Medication Costs

Medical management includes:

• Combined oral contraceptives and progestin-only pills (relatively low cost, but not always effective)
• GnRH agonists such as leuprolide acetate, which carry significant side-effect profiles including bone density loss with long-term use
• GnRH antagonists such as elagolix (Orilissa), which received FDA approval specifically for endometriosis-associated pain in 2018 and can cost over $800 per month without insurance coverage
• Aromatase inhibitors used off-label for refractory disease

The newer oral GnRH antagonists represent a meaningful clinical advance for women who cannot tolerate surgery or who need a bridge between procedures, but their price point creates access inequity that falls hardest on uninsured and underinsured women.

Imaging and Specialist Visits

Transvaginal ultrasound and MRI are increasingly used in endometriosis evaluation, particularly for deep infiltrating disease affecting the bladder or bowel. Each imaging study adds $200 to $1,500 depending on facility and insurance status. Women with complex disease may undergo multiple imaging studies per year.

Indirect Costs: Lost Wages, Productivity, and Career Trajectory

Indirect costs are harder to quantify but arguably more damaging to long-term financial wellbeing.

Absenteeism and Presenteeism

A study by Simoens and colleagues, published in Human Reproduction in 2012, found that women with endometriosis lost an average of 10.8 work hours per week, with presenteeism (being present but not fully functional) accounting for the majority of lost productivity, not absenteeism. This distinction matters: employers and insurers see absenteeism. They do not see the woman who is at her desk managing a 7/10 pain level, running at half capacity, missing nuance in meetings, and declining projects that require travel or unpredictable scheduling.

Presenteeism is invisible, uncompensated, and cumulative.

Career Progression

A woman who regularly misses deadlines, declines evening meetings, or requests flexible scheduling due to endometriosis symptoms may be perceived, consciously or not, as less committed. Research published in the journal Human Reproduction documented that women with endometriosis reported lower rates of career advancement and higher rates of job change than peers without the condition. Many described deliberately choosing lower-stakes roles to accommodate their symptoms, accepting a pay ceiling in exchange for scheduling flexibility.

This is a structural economic penalty that compounds over a career. A woman who earns $5,000 less per year for 20 years during her prime earning decades loses $100,000 in nominal wages before accounting for lost retirement contributions, forgone equity accumulation, and reduced Social Security benefits.

The $78 Billion Global Estimate

A landmark analysis by Simoens and colleagues estimated the global economic burden of endometriosis at approximately $78 billion annually when direct healthcare costs, productivity losses, and quality-of-life-adjusted measures are combined. This figure exceeds the economic burden of several better-funded conditions, including type 2 diabetes in some regional analyses, yet research funding for endometriosis has historically lagged far behind.

The following framework helps women and their clinicians categorize costs in a clinical conversation, because having language for the full burden can support advocacy with employers, insurers, and disability evaluators:

The Three-Layer Cost Model for Endometriosis:

1. Visible direct costs (bills, prescriptions, procedures) - documentable, insurable
2. Hidden direct costs (travel to specialist, childcare during appointments, OTC medications) - rarely tracked but real
3. Structural indirect costs (career suppression, foregone education, relationship strain) - almost never counted in economic analyses but often the largest long-term burden

Mental Health: The Economic Cost of Undertreated Pain

Chronic pain and mental health are inseparable. A systematic review published in Human Reproduction Update found that women with endometriosis experience depression at rates up to 50% and anxiety at rates up to 87%, substantially higher than age-matched controls.

Mental health costs add another economic layer:

• Therapy and psychiatric medication
• Reduced cognitive performance affecting work output
• Relationship strain that may lead to partnership dissolution and the financial consequences that follow
• Social isolation reducing professional network access

The directionality is not simple. Chronic pain causes psychological distress, but undertreated anxiety and depression also amplify pain perception. Women who finally receive adequate pain management often report simultaneous improvement in mental health, suggesting that the mental health burden is, at least partly, a downstream cost of inadequate endometriosis care.

ACOG's Practice Bulletin on Endometriosis does not yet include a standardized mental health screening protocol within endometriosis management guidelines, a gap that practicing clinicians at WomanRx have noted in patient care.

Fertility, Assisted Reproduction, and the Financial Cascade

Between 30 and 50% of women with endometriosis experience subfertility, according to ASRM's Practice Committee documentation. When natural conception is delayed or unsuccessful, women may pursue:

• Ovulation induction with oral agents (clomiphene or letrozole)
• Intrauterine insemination (IUI)
• In vitro fertilization (IVF)
• Egg freezing as a fertility-preservation strategy while managing active disease

IVF in the United States costs an average of $12,000 to $15,000 per cycle, and success rates are lower in women with endometriosis than in those without. Women with endometriomas (ovarian cysts caused by endometriosis) may require surgical removal before IVF, adding surgical cost and the risk of reduced ovarian reserve from the procedure itself.

Insurance coverage for fertility treatment remains inconsistent across states. As of 2024, only 20 states have fertility insurance mandate laws, and even mandated coverage frequently excludes IVF or applies to employer groups only. Women in non-mandate states bear the full cost privately.

Life Stage Note: Trying to Conceive in Your 30s

A woman who spends her mid-twenties in the diagnostic odyssey and her late twenties establishing a correct diagnosis and trying medical management may arrive at her early thirties with a compressed fertility window and active ovarian disease. The urgency of both managing endometriosis and pursuing conception simultaneously creates a clinical and financial pressure point that requires careful coordination between a reproductive endocrinologist, a gynecologic surgeon skilled in endometriosis, and a mental health provider.

Health Equity: Who Bears the Heaviest Burden?

The economic costs of endometriosis are not distributed equally. Several factors determine whether a woman can access timely, appropriate care.

Race and Ethnicity

The historical clinical myth that endometriosis is a "career woman's disease" affecting primarily white women has been thoroughly disproven. Research published in the American Journal of Obstetrics and Gynecology has documented that Black women with endometriosis wait significantly longer for diagnosis than white women with identical symptom profiles, are less likely to be referred for specialist evaluation, and are more likely to have their pain attributed to other causes.

Hispanic and Latina women face language barriers, cultural norms around discussing menstrual pain, and geographic distance from endometriosis specialists.

Women in lower income brackets, regardless of race, face the compounding effect of fewer paid sick days, higher cost-sharing in their insurance plans, and less access to telehealth services that might reduce travel burden.

Geographic Disparities

Excision surgery requires specialists. Those specialists cluster in urban academic centers. A woman in rural Mississippi or Wyoming faces travel costs, lodging, and additional time away from work that a woman in Boston or San Francisco does not. The clinical outcome difference between ablation (widely available) and excision (specialist-dependent) translates directly into a recurrence-rate difference, meaning geographic access shapes long-term surgical costs.

What Advocacy and Policy Changes Could Reduce the Burden

Several evidence-based changes at the policy level could meaningfully reduce the economic burden on women with endometriosis.

Earlier clinical recognition reduces the diagnostic delay and therefore compresses the years of accumulating costs without treatment. This requires training primary care providers and pediatricians to recognize adolescent endometriosis, as ACOG's 2018 Committee Opinion on adolescent endometriosis recommends.

Insurance coverage mandates for excision surgery would reduce the financial penalty for choosing the most effective surgical approach over the more widely covered but less durable ablation.

Paid medical leave protects women from the income loss that currently makes symptom management a luxury. The United States remains one of the few high-income countries without federal paid medical leave, a structural gap that falls disproportionately on women with chronic gynecological conditions.

Research funding parity matters because treatments improve when trials are funded. NIH funding for endometriosis research was approximately $16 million in fiscal year 2020, a figure that represents a small fraction of funding for conditions affecting comparable numbers of people.

What You Can Do Now: Practical Steps to Reduce Your Financial Exposure

Understanding the broader economic picture is useful. Knowing what actions you can take this week is more useful.

Document everything. Keep a symptom diary that records pain levels, work hours missed, medications used, and activities forgone. This documentation supports insurance appeals, disability accommodation requests, and conversations with your employer about flexible scheduling.

Request itemized bills. Medical billing errors are common. An itemized bill lets you identify duplicate charges, incorrect codes, and services you did not receive.

Ask your surgeon about excision vs. Ablation specifically. Ask for the surgeon's personal excision-to-ablation ratio and their recurrence data. Choosing excision when it is available to you may reduce the lifetime number of surgeries.

Explore patient assistance programs. AbbVie (manufacturer of elagolix/Orilissa) and AstraZeneca offer patient assistance for branded medications. The NeedyMeds database catalogs programs by drug name.

Connect with ACOG-affiliated patient advocacy resources. The Endometriosis Foundation of America and the World Endometriosis Research Foundation both maintain resources for navigating insurance and specialist access.

As WomanRx reviewer Elena Vasquez, MD, puts it: "The economic conversation is a clinical conversation. When I am not asking a patient about her work, her insurance gaps, and her out-of-pocket burden, I am missing information that directly affects which treatment plan she can actually sustain. A prescription for a $900-a-month medication is not a treatment plan for a woman without coverage. It is a frustration."

Who This Is Right for and Who Should Seek Specialist Care Urgently

Endometriosis management is not one-size-fits-all, and the economic stakes make choosing the right entry point important.

You are likely well-served by your current provider if:

• Your pain is controlled with first-line hormonal management
• You are not currently trying to conceive
• You have confirmed Stage I or II disease without deeply infiltrating lesions
• Your work and daily function are not significantly impaired

You should seek a specialist with dedicated endometriosis expertise if:

• Your pain is not controlled despite adequate hormonal management
• You have rectovaginal, bladder, or bowel involvement
• You are planning conception in the next 12 to 18 months
• You have had one or more prior surgeries with symptom recurrence
• Your disease is affecting your capacity to work or maintain daily function

The Endometriosis Foundation of America's surgeon directory and ASRM's specialist locator can help identify providers with specific endometriosis training in your region.